Monica Carbajales-Alvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Monica Carbajales-Alvarez has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ana Lozano-Blazquez
Unidad de Gestión Clínica de Farmacia, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
2 shared publications - Alberto Carmona-Bayonas
Department of Medical Oncology, Hospital General Universitario J.M. Morales Meseguer, Universidad de Murcia, UMU, IMIB, Murcia, Spain
1 shared publication Beatriz Fernández
Hospital de Cabueñes, Asturias, Spain
1 shared publicationBelén Rodríguez
Hospital de Cabueñes, Asturias, Spain
1 shared publication- Carmen Carriles-Fernandez
HUCA, Unidad Gest Clin Farm, Ave Roma S-N, Oviedo 33011, Asturias, Spain
1 shared publication Cecilia Calvo-Pita
Pharmacy Department, Primary Health Care, Servicio Madrileño de Salud, Dirección Asistencial Oeste, Madrid, Spain
1 shared publication
Latest Publications
- 17 June 2019
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 21 (12) , 1781-1785
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
Our aim was to assess efficacy and safety and prognostic factors associated with TAS-102 in clinical practice.
- 17 June 2019
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 21 (12) , 1781-1785
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
Our aim was to assess efficacy and safety and prognostic factors associated with TAS-102 in clinical practice.
- 2 June 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (3) , 549-555
Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma
Background: We describe the feasibility and safety of an oral administration schedule of hydration, alkalinization and leucovorin rescue with an ambulatory high-dose methotrexate regimen. Methods: Single-centre prospective observational study conducted within a tertiary hospital where all patients have received systemic high-dose methotrexate (3.5 g/m2). Patients were instructed to keep an adequate ambulatory oral hydration and alkalinization to monitor urine pH and to adjust bicarbonate according to our institution's treatment protocol. High-dose methotrexate was infused over 4 h. Urine pH was checked before high-dose methotrexate administration, and for any value less than 7 a sodium bicarbonate bolus was given. Leucovorin at a standard dose was begun 24 h after high-dose methotrexate. methotrexate serum concentrations were monitored daily from 24 h after administration until clearance (level ≤ 0.1 µmol/L). Results: From January 2016 to June 2018, 49 ambulatory high-dose methotrexate courses were given to 18 patients. No dose reduction was required afterwards. All patients completed succesfully the planned three doses in an outpatient basis, except four patients, one of them due to pneumonitis. Previous to methotrexate infusion, urinary pH > 7 was achieved in 35 (79.5%) cycles. Methotrexate clearance was achieved by 72 h in 35 courses (71.4%), and by 96 h in 100%. Neutropenia/trombocytopenia grades III/IV were observed in four cycles (8.16%) and two (4.08%) cycles, respectively. Around 20.40% were associated with stomatitis, 14.20% vomiting, 10.20% asthenia, 8.16% diarrhea and 6.12% with renal toxicity. Conclusions: Ambulatory administration of high-dose methotrexate as CNS prophylaxis is safe and feasible following the described approach, allowing us to optimize healthcare resources.
- 2 June 2019
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 26 (3) , 549-555
Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma
Background: We describe the feasibility and safety of an oral administration schedule of hydration, alkalinization and leucovorin rescue with an ambulatory high-dose methotrexate regimen. Methods: Single-centre prospective observational study conducted within a tertiary hospital where all patients have received systemic high-dose methotrexate (3.5 g/m2). Patients were instructed to keep an adequate ambulatory oral hydration and alkalinization to monitor urine pH and to adjust bicarbonate according to our institution's treatment protocol. High-dose methotrexate was infused over 4 h. Urine pH was checked before high-dose methotrexate administration, and for any value less than 7 a sodium bicarbonate bolus was given. Leucovorin at a standard dose was begun 24 h after high-dose methotrexate. methotrexate serum concentrations were monitored daily from 24 h after administration until clearance (level ≤ 0.1 µmol/L). Results: From January 2016 to June 2018, 49 ambulatory high-dose methotrexate courses were given to 18 patients. No dose reduction was required afterwards. All patients completed succesfully the planned three doses in an outpatient basis, except four patients, one of them due to pneumonitis. Previous to methotrexate infusion, urinary pH > 7 was achieved in 35 (79.5%) cycles. Methotrexate clearance was achieved by 72 h in 35 courses (71.4%), and by 96 h in 100%. Neutropenia/trombocytopenia grades III/IV were observed in four cycles (8.16%) and two (4.08%) cycles, respectively. Around 20.40% were associated with stomatitis, 14.20% vomiting, 10.20% asthenia, 8.16% diarrhea and 6.12% with renal toxicity. Conclusions: Ambulatory administration of high-dose methotrexate as CNS prophylaxis is safe and feasible following the described approach, allowing us to optimize healthcare resources.
- Open Access
- 1 July 2014
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 10, 527-35
Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice
Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice Ana Lozano-Blázquez,1 Cecilia Calvo-Pita,2 Mónica Carbajales-Álvarez,1 Patricio Suárez-Gil,3 Fernando Martínez-Martínez,4 Miguel Ángel Calleja-Hernández51Pharmacy Department, Hospital de Cabueñes, Gijón, Spain; 2Pharmacy Department, Primary Health Care, Servicio Madrileño de Salud, Dirección Asistencial Oeste, Madrid, Spain; 3Research Unit Área V, Hospital de Cabueñes, Gijón, Spain; 4Responsable del Grupo de Investigación en Atención Farmacéutica, Universidad de Granada, 5UGC Provincial de Farmacia de Granada Instituto de Biomedicina de Granada, Hospital Virgen de las Nieves, Granada, SpainBackground: In Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use.Methods: This was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee's activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria.Results: The PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma.Conclusion: The degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.Keywords: decision-making, drug selection, drug utilization, formulary, neoplasm, Pharmacy and Therapeutics committee
- 1 July 2014
- Published by Taylor & Francis in Therapeutics and Clinical Risk Management
- Vol. 10, 527-35
Open AccessDrug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice
Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice Ana Lozano-Blázquez,1 Cecilia Calvo-Pita,2 Mónica Carbajales-Álvarez,1 Patricio Suárez-Gil,3 Fernando Martínez-Martínez,4 Miguel Ángel Calleja-Hernández51Pharmacy Department, Hospital de Cabueñes, Gijón, Spain; 2Pharmacy Department, Primary Health Care, Servicio Madrileño de Salud, Dirección Asistencial Oeste, Madrid, Spain; 3Research Unit Área V, Hospital de Cabueñes, Gijón, Spain; 4Responsable del Grupo de Investigación en Atención Farmacéutica, Universidad de Granada, 5UGC Provincial de Farmacia de Granada Instituto de Biomedicina de Granada, Hospital Virgen de las Nieves, Granada, SpainBackground: In Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use.Methods: This was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee's activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria.Results: The PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma.Conclusion: The degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.Keywords: decision-making, drug selection, drug utilization, formulary, neoplasm, Pharmacy and Therapeutics committee
- 27 December 2005
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 298 (1) , 363-368
The effect of octyl glucoside on rheological behavior of diluted and concentrated lamellar phases
- 27 December 2005
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 298 (1) , 363-368
The effect of octyl glucoside on rheological behavior of diluted and concentrated lamellar phases
- 1 August 2002
- Published by Springer Nature in Infection
- Vol. 30 (4) , 240-242
Eikenella corrodens Brain Abscess after Repeated Periodontal Manipulations Cured with Imipenem and Neurosurgery
Eikenella corrodens is a facultatively anaerobic gramnegative rod that colonizes the oral cavity and very rarely produces central nervous system (CNS) infections. Frontal lobe abscesses are occasionally associated with a dental source of infection. We report a case of an adult man with overzealous dental cleaning habits who developed a right frontal brain abscess caused by E. corrodens. He underwent neurosurgical drainage of the pus and was successfully treated with imipenem 4 g/iv/day for 4 weeks with no complications. Repeated periodontal trauma could explain the Eikenella brain abscess in this case.
- 1 August 2002
- Published by Springer Nature in Infection
- Vol. 30 (4) , 240-242
Eikenella corrodens Brain Abscess after Repeated Periodontal Manipulations Cured with Imipenem and Neurosurgery
Eikenella corrodens is a facultatively anaerobic gramnegative rod that colonizes the oral cavity and very rarely produces central nervous system (CNS) infections. Frontal lobe abscesses are occasionally associated with a dental source of infection. We report a case of an adult man with overzealous dental cleaning habits who developed a right frontal brain abscess caused by E. corrodens. He underwent neurosurgical drainage of the pus and was successfully treated with imipenem 4 g/iv/day for 4 weeks with no complications. Repeated periodontal trauma could explain the Eikenella brain abscess in this case.